Akèy › Kasinom Selil Transizyonèl (Urotelyal) › Texas
Etid klinik pou Kasinom Selil Transizyonèl (Urotelyal) nan Texas
38 etid pou Kasinom Selil Transizyonèl (Urotelyal) ap chèche patisipan nan sit nan Texas.
Vil nan Texas
- Dallas18 etid
- Houston18 etid
- San Antonio11 etid
- Austin10 etid
- The Woodlands5 etid
- Fort Worth5 etid
- Tyler4 etid
- Irving3 etid
- League City3 etid
- Sugar Land3 etid
Tèks ofisyèl etid la (Anglè)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- ak 1 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #46, Austin
- Exelixis Clinical Site #89, Dallas
- Exelixis Clinical Site #73, Irving
- ak 2 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- Houston Methodist San Jacinto Hospital, Baytown
- Houston Methodist Cypress Hospital, Cypress
- Parkland Memorial Hospital, Dallas
- ak 10 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06524544A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- ak 3 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Texas Oncology, Austin
- Texas Oncology - Northeast Texas, Tyler
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07566156Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- UT Southwestern Medical Center, Dallas
- The University of Texas M.D. Anderson Cancer Center, Houston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05874921DBC-664 in Adult Patients With Solid Tumors
- START San Antonio, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07705035Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Texas Oncology - Central/South Texas, Austin
- Texas Oncology - Central/South Texas, Austin
- Texas Oncology - Central/South Texas, Austin
- ak 13 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- START Dallas Fort Worth, Fort Worth
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
- ak 1 plis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07277413Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- USO-Texas Oncology-Central/South Texas, Austin
- World Research Link, Baytown
- Parkland Health and Hospital System, Dallas
- ak 5 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218380Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06439836A Study of GEN1106 in Participants With Solid Tumors
- South Texas Accelerated Research Therapeutics, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT07416123Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Start - Dfw, Fort Worth
- Oncology Consultants, Houston
- START - San Antonio, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
- UPNT Research Institute, LLC, Arlington
- Texas Urology Specialists-Austin, Austin
- Houston Metro Urology (HMU) - Southwest Location, Houston
- ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06774131Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- START San Antonio, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06582017Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Dallas
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07129993Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- NEXT Oncology, Austin, Austin
- NEXT Oncology, San Antonio, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06966024A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Houston Methodist Hospital, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT04895709A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT04198766An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Dallas
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07720284A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Baylor Scott and White Research Institute, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center - Temple, Temple
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT04879329A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Texas Oncology - DFW, Dallas
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- MD Anderson Cancer Center, Houston
- Next Oncology-Oncology, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT07169734Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
- Austin Urology Institute, Austin
- UT Southwestern Medical Center, Dallas
Ap rekrite
Laj 18 a 88 · Tout sèks · Mizajou Jul 2, 2026 · NCT06394869Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
- UT Southwestern Medical Center, Dallas
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07673016Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
- MDACC, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT07484022Bladder Cancer Screening Trial
- University of Texas Southwestern Medical Center, Dallas
Ap rekrite
Laj 50 ak plis · Tout sèks · Mizajou May 1, 2026 · NCT05646485Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
- M D Anderson Cancer Center, Houston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT04693377This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- NEXT Oncology, Austin, TX 78758
- NEXT Oncology, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 2, 2026 · NCT06451497An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
- University of Texas Southwestern Medical Center, Dallas
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jan 28, 2026 · NCT04623502A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Austin
- Dren Investigational Site, Dallas
- Dren Investigational Site, San Antonio
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jan 7, 2026 · NCT06999187A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Dec 11, 2025 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT05107674Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.